Aurobindo Pharma Limited
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Aurobindo Pharma Limited's past years’ income statements indicate that its last revenue has increased compared to the previous period by 24% to $290,018,700,000. The net income raised on $31,729,700,000 and profit margin reached 11%. Total operating expenses were $55,657,900,000.
Profit Margin
| 2010 | 35.75B | 5.63B | 15.76% |
|---|---|---|---|
| 2011 | 43.81B | 5.63B | 12.86% |
| 2012 | 45.53B | -1.23B | -2.71% |
| 2015 | 120.42B | 15.75B | 13.08% |
| 2016 | 136.49B | 19.82B | 14.52% |
| 2018 | 161.99B | 24.23B | 14.96% |
| 2019 | 192.25B | 23.64B | 12.3% |
| 2021 | 245.57B | 53.34B | 21.72% |
| 2022 | 233.66B | 26.48B | 11.33% |
| 2024 | 290.01B | 31.72B | 10.94% |
AUROPHARMA.NS Income Statement (2010 – 2023)
| 2023 | 2021 | 2020 | 2018 | 2017 | 2015 | 2014 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 290.01B | 233.66B | 245.57B | 192.25B | 161.99B | 136.49B | 120.42B | 45.53B | 43.81B | 35.75B |
Cost of revenue | 129.85B | 101.40B | 99.02B | 87.12B | 67.52B | 61.57B | 55.05B | 25.19B | 22.41B | 15.94B |
Gross profit | 160.16B | 132.26B | 146.55B | 105.13B | 94.46B | 74.91B | 65.37B | 20.33B | 21.39B | 19.81B |
Operating exp. | ||||||||||
Research and development | 15.22B | 652.4M | 688.1M | 756.3M | 292.2M | 150.6M | 253M | 49.9M | 0 | 0 |
Selling and marketing | 16.84B | 15.68B | 16.43B | 11.92B | 10.90B | 9.46B | 9.34B | 2.30B | 0 | 0 |
Total operating expenses | 55.65B | 99.28B | 101.79B | 72.04B | 61.79B | 46.27B | 42.11B | 16.02B | 12.78B | 11.61B |
Operating income | 104.50B | 33.06B | 44.53B | 33.08B | 32.67B | 28.64B | 23.26B | 4.31B | 8.60B | 8.20B |
Other income (expenses), net | -60.70B | 663.1M | -20.59B | -2.17B | -262.4M | -1.02B | -1.58B | -6.44B | 624.6M | 678M |
Income before tax | 43.79B | 33.72B | 73.43B | 30.91B | 32.41B | 27.22B | 21.67B | -2.12B | 7.98B | 7.52B |
Income tax expense | 12.11B | 7.25B | 20.09B | 7.26B | 8.18B | 7.44B | 5.96B | -888.1M | 2.25B | 1.91B |
Net income | 31.72B | 26.48B | 53.34B | 23.64B | 24.23B | 19.82B | 15.75B | -1.23B | 5.63B | 5.63B |
Earnings per share | ||||||||||
Basic EPS | 54.16 | 45.2 | 91.05 | 40.36 | 41.36 | 34.67 | 27.03 | -2.12 | 9.78 | 10.40 |
Diluted EPS | 54.15 | 45.2 | 91.05 | 40.36 | 41.36 | 34.66 | 27 | -2.12 | 8.80 | 8.91 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |